Introduction:
The biologic therapies market in the United States is projected to see significant growth by 2026, driven by increasing demand for innovative treatment options and advancements in biotechnology. According to industry reports, the biologics market in the US is expected to reach $125 billion by 2026, with a compound annual growth rate of 8%. This market report will highlight the top 10 biologic therapies brands in the United States for 2026.
Top 10 Biologic Therapies Brands in United States 2026:
1. Humira (AbbVie)
– Market Share: 15%
– Humira continues to be a top-selling biologic therapy for conditions such as rheumatoid arthritis and psoriasis, maintaining its leading position in the US market.
2. Keytruda (Merck)
– Market Share: 10%
– Keytruda has emerged as a leading immunotherapy for various types of cancer, with strong sales growth and widespread adoption in the United States.
3. Remicade (Janssen Biotech)
– Market Share: 8%
– Remicade remains a key player in the biologic therapies market, particularly for autoimmune disorders like Crohn’s disease and ulcerative colitis.
4. Enbrel (Amgen)
– Market Share: 7%
– Enbrel is a popular choice for treating autoimmune diseases such as rheumatoid arthritis and psoriasis, contributing significantly to Amgen’s revenue in the US.
5. Rituxan (Genentech)
– Market Share: 6%
– Rituxan continues to be a top-selling biologic therapy for non-Hodgkin’s lymphoma and rheumatoid arthritis, maintaining a strong presence in the US market.
6. Avastin (Genentech)
– Market Share: 5%
– Avastin is a widely used biologic therapy for various cancers, including colorectal, lung, and breast cancer, making it a key player in the US market.
7. Herceptin (Genentech)
– Market Share: 4%
– Herceptin remains a leading biologic therapy for HER2-positive breast cancer, with consistent sales growth and high demand in the United States.
8. Stelara (Janssen Biotech)
– Market Share: 3%
– Stelara is a growing biologic therapy for psoriasis and Crohn’s disease, with increasing adoption among patients and healthcare providers in the US.
9. Opdivo (Bristol-Myers Squibb)
– Market Share: 2%
– Opdivo has gained traction as an immunotherapy for various cancers, including melanoma and lung cancer, driving revenue growth for Bristol-Myers Squibb in the US market.
10. Xeljanz (Pfizer)
– Market Share: 2%
– Xeljanz is a key biologic therapy for rheumatoid arthritis and ulcerative colitis, contributing to Pfizer’s strong presence in the US biologics market.
Insights:
The biologic therapies market in the United States is poised for continued growth, driven by increasing demand for innovative treatment options and advancements in biotechnology. With a projected market size of $125 billion by 2026 and a compound annual growth rate of 8%, the US remains a key market for biologic therapies. Companies that focus on research and development to bring new and effective biologic therapies to market are likely to succeed in this competitive landscape. Additionally, the rise of immunotherapies like Keytruda and Opdivo highlights the growing importance of personalized medicine in the treatment of various cancers. As the healthcare industry continues to evolve, biologic therapies are expected to play a significant role in shaping the future of patient care in the United States.
Related Analysis: View Previous Industry Report
